Recommended

GSK appoints new CEO
New webinar | Addressing the time-to-result challenge posed by short shelf-life radiopharmaceuticals, register today
Genmab acquires biotech Merus for $8bn
US FDA licensing first for IL-23 inhibitor to treat paediatric psoriasis
Teva makes progress on API business divestment
Takeda to move away from cell therapy
news

Sanofi collaboration to advance innovative radioligand therapies

2
SHARES

The new partnership between Sanofi and Orano Med, delivered via a new entity valued at nearly $2 billion, will focus on progressing lead-212 based targeted alpha therapies for oncology indications.

radioligand therapies Sanofi

Sanofi Orano Med (subsidiary of the Orano Group) have agreed a new collaboration to advance development of next-generation radioligand therapies for rare cancers.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

As part of the agreement, the two parties will invest in a new entity, valued at €1.9 billion. It will operate under Orano Med and focus on creating and trialling next-generation lead-212 (212Pb) radioligand therapies.

Sanofi will make an equity investment of €300 million, enabling Orano Med to accelerate the development of its pipeline, leveraging the company’s capabilities in lead-212 based therapy discovery and development.

This news follows a licensing agreement announced last month between Orano Med and RadioMedix, to advance radioligand therapies in rare cancers with a focus on the late-stage project AlphaMedix™ (212Pb-DOTAMTATE).

Potential of lead-212 based radioligand therapies

“Sanofi’s partnership with Orano Med is a strong recognition of the potential of lead-212 based radioligand therapies to advance the treatment of cancers,” remarked Julien Dodet, President of the Governing Board, Orano Med. She added that the company is looking forward to advancing the development of these “potentially transformative therapies”.

“Sanofi’s partnership with Orano Med is a strong recognition of the potential of lead-212 based radioligand therapies to advance the treatment of cancers”

“We are excited to partner with Orano in establishing a French pioneer that unites our respective expertise in biopharma and nuclear technology to drive ground-breaking progress in the fight against cancer,” commented Paul Hudson, CEO, Sanofi.

Sanofi and Orano Med look forward to contributing to the agenda of the France 2030 plan, according to Sanofi. Last month, the company inaugurated a novel production unit in France, supporting the country’s ambitions around medicine innovation.

This collaboration agreement between Sanofi and Orano to develop radioligand therapies is subject to regulatory approvals.

Innovative radioligand manufacturing facility inaugurated

Share via
Share via